# Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

> **NCT03961932** · PHASE1 · COMPLETED · sponsor: **ObsEva SA** · enrollment: 33 (actual)

## Conditions studied

- Renal Impairment
- Healthy Participants

## Interventions

- **DRUG:** Linzagolix

## Key facts

- **NCT ID:** NCT03961932
- **Lead sponsor:** ObsEva SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-15
- **Primary completion:** 2020-01-22
- **Final completion:** 2020-01-31
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03961932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03961932, "Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03961932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*